Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Study protocol

Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI

Authors: Edith Pituskin, Mark Haykowsky, John R Mackey, Richard B Thompson, Justin Ezekowitz, Sheri Koshman, Gavin Oudit, Kelvin Chow, Joseph J Pagano, Ian Paterson

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

MANTICORE 101 - Breast (Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research) is a randomized trial to determine if conventional heart failure pharmacotherapy (angiotensin converting enzyme inhibitor or beta-blocker) can prevent trastuzumab-mediated left ventricular remodeling, measured with cardiac MRI, among patients with HER2+ early breast cancer.

Methods/Design

One hundred and fifty-nine patients with histologically confirmed HER2+ breast cancer will be enrolled in a parallel 3-arm, randomized, placebo controlled, double-blind design. After baseline assessments, participants will be randomized in a 1:1:1 ratio to an angiotensin-converting enzyme inhibitor (perindopril), beta-blocker (bisoprolol), or placebo. Participants will receive drug or placebo for 1 year beginning 7 days before trastuzumab therapy. Dosages for all groups will be systematically up-titrated, as tolerated, at 1 week intervals for a total of 3 weeks. The primary objective of this randomized clinical trial is to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer, as measured by 12 month change in left ventricular end-diastolic volume using cardiac MRI. Secondary objectives include 1) determine the evolution of left ventricular remodeling on cardiac MRI in patients with HER2+ early breast cancer, 2) understand the mechanism of trastuzumab mediated cardiac toxicity by assessing for the presence of myocardial injury and apoptosis on serum biomarkers and cardiac MRI, and 3) correlate cardiac biomarkers of myocyte injury and extra-cellular matrix remodeling with left ventricular remodeling on cardiac MRI in patients with HER2+ early breast cancer.

Discussion

Cardiac toxicity as a result of cancer therapies is now recognized as a significant health problem of increasing prevalence. To our knowledge, MANTICORE will be the first randomized trial testing proven heart failure pharmacotherapy in the prevention of trastuzumab-mediated cardiotoxicity. We expect the findings of this trial to provide important evidence in the development of guidelines for preventive therapy.

Trial Registration

ClinicalTrials.gov: NCT01016886
Appendix
Available only for authorised users
Literature
1.
Canadian Cancer Statistics. 2010, Toronto, Canada, 0835-2976.
2.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235 (4785): 177-182. 10.1126/science.3798106.CrossRefPubMed
3.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244 (4905): 707-712. 10.1126/science.2470152.CrossRefPubMed
4.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344 (11): 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed
5.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002, 20 (3): 719-726. 10.1200/JCO.20.3.719.CrossRefPubMed
6.
Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P: Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005, 23 (10): 2162-2171. 10.1200/JCO.2005.01.014.CrossRefPubMed
7.
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005, 23 (19): 4265-4274. 10.1200/JCO.2005.04.173.CrossRefPubMed
8.
Baselga J, Perez EA, Pienkowski T, Bell R: Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006, 11 (Suppl 1): 4-12.CrossRefPubMed
9.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005, 353 (16): 1673-1684. 10.1056/NEJMoa052122.CrossRefPubMed
10.
Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007, 25 (25): 3859-3865. 10.1200/JCO.2006.09.1611.CrossRefPubMed
11.
Slamon DJ, Robert N, et al: Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: a second interim efficacy analysis. San Antonio Breast Cancer Symposium: 2006. 2006, San Antonio, TX
12.
Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ: Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment. J Clin Oncol. 2005, 23 (31): 7820-7826. 10.1200/JCO.2005.13.300.CrossRefPubMed
13.
Wadhwa D, Fallah-Rad N, Grenier D, Krahn M, Fang T, Ahmadie R, Walker JR, Lister D, Arora RC, Barac I, et al: Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat. 2009, 117 (2): 357-364. 10.1007/s10549-008-0260-6.CrossRefPubMed
14.
McArthur HL, Chia S: Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med. 2007, 357 (1): 94-95. 10.1056/NEJMc070065.CrossRefPubMed
15.
Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000, 35 (3): 569-582. 10.1016/S0735-1097(99)00630-0.CrossRefPubMed
16.
Mann DL, Bristow MR: Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond. Circulation. 2005, 111 (21): 2837-2849. 10.1161/CIRCULATIONAHA.104.500546.CrossRefPubMed
17.
Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D: Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 1997, 336 (19): 1350-1355. 10.1056/NEJM199705083361903.CrossRefPubMed
18.
Haykowsky MJ, Liang Y, Pechter D, Jones LW, McAlister FA, Clark AM: A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. J Am Coll Cardiol. 2007, 49 (24): 2329-2336. 10.1016/j.jacc.2007.02.055.CrossRefPubMed
19.
Haykowsky MJ, Mackey JR, Thompson RB, Jones LW, Paterson DI: Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training. Clin Cancer Res. 2009, 15 (15): 4963-4967. 10.1158/1078-0432.CCR-09-0628.CrossRefPubMed
20.
Telli ML, Hunt SA, Carlson RW, Guardino AE: Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility. J Clin Oncol. 2007, 25 (23): 3525-3533. 10.1200/JCO.2007.11.0106.CrossRefPubMed
21.
St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S, et al: Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994, 89 (1): 68-75.CrossRefPubMed
22.
Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B: Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995, 91 (10): 2573-2581.CrossRefPubMed
23.
Ferrari R: Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006, 166 (6): 659-666.CrossRefPubMed
24.
Abdulla J, Barlera S, Latini R, Kjoller-Hansen L, Sogaard P, Christensen E, Kober L, Torp-Pedersen C: A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail. 2007, 9 (2): 129-135. 10.1016/j.ejheart.2006.05.002.CrossRefPubMed
25.
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet. 1997, 349 (9049): 375-380.
26.
Bellenger NG, Rajappan K, Rahman SL, Lahiri A, Raval U, Webster J, Murray GD, Coats AJ, Cleland JG, Pennell DJ: Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart. 2004, 90 (7): 760-764. 10.1136/hrt.2003.015552.CrossRefPubMedPubMedCentral
27.
Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, et al: Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. Journal of the American College of Cardiology. 2006, 48 (11): 2258-2262. 10.1016/j.jacc.2006.07.052.CrossRefPubMed
28.
Cardinale D, Lamantia G, Cipolla CM: Troponin I and cardiovascular risk stratification in patients with testicular cancer. J Clin Oncol. 2006, 24 (21): 3508-author reply 3508-3509CrossRefPubMed
29.
Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC, Shaikh SL, Mone SM, Gelber RD, Colan SD: Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002, 20 (23): 4517-4522. 10.1200/JCO.2002.12.102.CrossRefPubMed
30.
Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, et al: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006, 48 (11): 2258-2262. 10.1016/j.jacc.2006.07.052.CrossRefPubMed
31.
Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000, 36 (2): 517-522. 10.1016/S0735-1097(00)00748-8.CrossRefPubMed
32.
Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973, 32 (2): 302-314. 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2.CrossRefPubMed
33.
Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH: Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. Eur Heart J. 2009, 30 (1): 98-106.CrossRefPubMed
34.
Bellenger N, Pennell D: Magnetic resonance imaging in cardiology. J R Coll Physicians Lond. 1999, 33 (1): 12-18.PubMed
35.
Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ: Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2000, 2 (4): 271-278. 10.3109/10976640009148691.CrossRefPubMed
36.
Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ: Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?. Eur Heart J. 2000, 21 (16): 1387-1396. 10.1053/euhj.2000.2011.CrossRefPubMed
37.
Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, et al: Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 28 (25): 3910-3916.
38.
Lenihan DJMM, Baysinger KB, et al: Superior detection of cardiotoxicity during chemotherapy using biomarkers. Heart Failure Society of America: September 17 2007. 2007, Washington, DC
39.
Cardinale D, Sandri MT: Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis. 53 (2): 121-129.
40.
Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martinez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, et al: Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000, 101 (14): 1729-1735.CrossRefPubMed
41.
Braunwald E: Biomarkers in Heart Failure. N Engl J Med. 2008, 358 (20): 2148-2159. 10.1056/NEJMra0800239.CrossRefPubMed
42.
Cicoira M, Rossi A, Bonapace S, Zanolla L, Golia G, Franceschini L, Caruso B, Marino PN, Zardini P: Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail. 2004, 10 (5): 403-411. 10.1016/j.cardfail.2004.01.010.CrossRefPubMed
43.
Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000, 102 (22): 2700-2706.CrossRefPubMed
44.
Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, Vincent J, Pitt B, Zannad F: Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation. 2009, 119 (18): 2471-2479. 10.1161/CIRCULATIONAHA.108.809194.CrossRefPubMed
45.
Lopez B, Gonzalez A, Diez J: Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 121 (14): 1645-1654.
46.
Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007, 369 (9555): 29-36. 10.1016/S0140-6736(07)60028-2.CrossRefPubMed
47.
Mazurek S, Eigenbrodt E: The tumor metabolome. Anticancer Res. 2003, 23 (2A): 1149-1154.PubMed
48.
Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, Faught W, Sawyer MB: Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res. 16 (23): 5835-5841.
49.
Samuel JL, Schaub MC, Zaugg M, Mamas M, Dunn WB, Swynghedauw B: Genomics in cardiac metabolism. Cardiovasc Res. 2008, 79 (2): 218-227. 10.1093/cvr/cvn061.CrossRefPubMed
50.
Marziliano N, Grasso M, Pilotto A, Porcu E, Tagliani M, Disabella E, Diegoli M, Pasotti M, Favalli V, Serio A, et al: Transcriptomic and proteomic analysis in the cardiovascular setting: unravelling the disease?. J Cardiovasc Med (Hagerstown). 2009, 10 (5): 433-442. 10.2459/JCM.0b013e328324e972.CrossRef
51.
Damaraju SSB, Ghosh S, Pituskin E, Tuszynski J, Cass CE, Mackey JR: Germline copy number polymorphisms associated with toxicity from adjuvant docetaxel. San Antonio Breast Cancer Symposium: December 8-12 2010. 2010, San Antonio TX
52.
Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR: Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007, 50 (15): 1435-1441. 10.1016/j.jacc.2007.06.037.CrossRefPubMed
Metadata
Title
Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI
Authors
Edith Pituskin
Mark Haykowsky
John R Mackey
Richard B Thompson
Justin Ezekowitz
Sheri Koshman
Gavin Oudit
Kelvin Chow
Joseph J Pagano
Ian Paterson
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-318

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Expression profile of the N-myc Downstream Regulated Gene 2 (NDRG2) in human cancers with focus on breast cancer

Research article

Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells

Research article

A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis

Research article

Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways

Research article

Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1Cin pancreatic endocrine tumors

Research article

Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits